Sign in or create an account to add this stock to your watchlist.
About Epizyme (NASDAQ:EPZM)
Epizyme, Inc., a clinical stage biopharmaceutical company, discovers and develops novel epigenetic medicines for patients with cancer and other diseases in the United States. Its product candidates include tazemetostat, an inhibitor of the EZH2, which is in Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma (NHL); Phase II clinical trial for relapsed or refractory patients with mesothelioma; Phase I dose-escalation and expansion study for children with INI1-negative solid tumors; Phase II clinical trials for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL); Phase Ib/II clinical trial in elderly patients with DLBCL; and Phase II clinical trial for relapsed or refractory patients with mesothelioma characterized by BAP1 loss-of-function,; and Phase Ib/II clinical trial for the treatment of patients with relapsed or refractory metastatic non-small cell lung cancer, as well as Phase II clinical trial in adult patients with ovarian cancer. The company is also developing additional programs, such as pinometostat, an intravenously administered small molecule inhibitor of DOT1L for the treatment of acute leukemias; and PRMT5 inhibitor that is in Phase I clinical trial for patients with solid tumors and NHL. It has collaboration agreements with Celgene Corporation, Genentech Inc., and Glaxo Group Limited, as well as with Roche Molecular Systems, Inc., Eisai Co. Ltd., and Lymphoma Study Association. Epizyme, Inc. was founded in 2007 and is headquartered in Cambridge, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:EPZM
CUSIPN/A
Phone617-229-5872
Debt
Debt-to-Equity RatioN/A
Current Ratio10.43
Quick Ratio10.43
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$10 million
Price / Sales118.13
Cash FlowN/A
Price / CashN/A
Book Value$3.33 per share
Price / Book5.11
Profitability
EPS (Most Recent Fiscal Year)($2.18)
Net Income$-134,300,000.00
Net MarginsN/A
Return on Equity-61.42%
Return on Assets-50.53%
Miscellaneous
Employees131
Outstanding Shares69,490,000
Epizyme (NASDAQ:EPZM) Frequently Asked Questions
What is Epizyme's stock symbol?
Epizyme trades on the NASDAQ under the ticker symbol "EPZM."
How were Epizyme's earnings last quarter?
Epizyme (NASDAQ:EPZM) released its quarterly earnings results on Tuesday, May, 8th. The biopharmaceutical company reported ($0.49) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.54) by $0.05. During the same quarter in the prior year, the company posted ($0.56) EPS. View Epizyme's Earnings History.
When is Epizyme's next earnings date?
What price target have analysts set for EPZM?
12 equities research analysts have issued 1-year price objectives for Epizyme's stock. Their forecasts range from $16.00 to $26.00. On average, they expect Epizyme's share price to reach $23.00 in the next year. View Analyst Ratings for Epizyme.
What are Wall Street analysts saying about Epizyme stock?
Here are some recent quotes from research analysts about Epizyme stock:
- 1. According to Zacks Investment Research, "Epizyme reported narrower than expected loss in the fourth quarter of 2017. Epizyme's efforts on developing its lead candidate, tazemetostat, for a number of hematological malignancies and genetically defined solid tumors are impressive. During the fourth quarter of 2017, the company had a productive interaction with the FDA to design the registration strategy for tazemetostat for epithelioid sarcomaand follicular lymphoma (FL) and identified a path to submit for accelerated approval for both the indications. The company plans to file a first new drug application of tazemetostat for epithelioid sarcoma in fourth quarter of 2018 and second NDA for FL in 2019. A potential approval for the candidate will be a significant boost for the company. So far this year, Epizyme’s share price has also outperformed the industry. However, the company is highly dependent on its collaboration partners for top-line growth with no approved product." (3/16/2018)
- 2. Cann analysts commented, "Epizyme presented two posters at the American Society of Hematology Meeting on December 10-11, 2017. These included a biomarker study in non-Hodgkin’s lymphoma (NHL) and preliminary response data from the diffuse large B cell lymphoma (DLBCL) cohort from the ongoing phase II study of tazemetostat in NHL. The data presented is very supportive of our outlook." (12/12/2017)
Who are some of Epizyme's key competitors?
Some companies that are related to Epizyme include United Therapeutics (UTHR), Taro Pharmaceutical Industries (TARO), Hutchison China MediTech (HCM), GW Pharmaceuticals (GWPH), FibroGen (FGEN), Ligand Pharmaceuticals (LGND), Blueprint Medicines (BPMC), Array Biopharma (ARRY), Ultragenyx Pharmaceutical (RARE), Amicus Therapeutics (FOLD), Supernus Pharmaceuticals (SUPN), Ascendis Pharma (ASND), Ironwood Pharmaceuticals (IRWD), Portola Pharmaceuticals (PTLA) and Clovis Oncology (CLVS).
Who are Epizyme's key executives?
Epizyme's management team includes the folowing people:
- Mr. Robert B. Bazemore Jr., Pres, CEO, Sec. & Director (Age 50)
- Dr. H. Robert Horvitz Ph.D., M.D., Co-Founder and Chairman of the Scientific Advisory Board
- Dr. Yi Zhang Ph.D., Scientific Co-Founder and Member of The Scientific Advisory Board
- Mr. Matthew E. Ros, Chief Operating Officer (Age 51)
- Dr. Michael Boretti, VP of Bus. Devel.
Has Epizyme been receiving favorable news coverage?
Media coverage about EPZM stock has been trending positive this week, according to Accern Sentiment Analysis. Accern identifies positive and negative news coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Epizyme earned a media sentiment score of 0.33 on Accern's scale. They also assigned news headlines about the biopharmaceutical company an impact score of 48.99 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company's share price in the near term.
Who are Epizyme's major shareholders?
Epizyme's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Palo Alto Investors LP (9.92%), BlackRock Inc. (5.61%), Redmile Group LLC (2.90%), Rock Springs Capital Management LP (1.83%), Millennium Management LLC (1.23%) and Point72 Asset Management L.P. (1.08%). Company insiders that own Epizyme stock include Andrew E Singer, David M Mott, Matthew Ros, Peter Tai-Ching Ho and Robert A Copeland. View Institutional Ownership Trends for Epizyme.
Which institutional investors are selling Epizyme stock?
EPZM stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, BlackRock Inc., University of Notre Dame DU Lac, Citigroup Inc., Rock Springs Capital Management LP, Barclays PLC and Teacher Retirement System of Texas. Company insiders that have sold Epizyme company stock in the last year include Andrew E Singer, Matthew Ros, Peter Tai-Ching Ho and Robert A Copeland. View Insider Buying and Selling for Epizyme.
Which institutional investors are buying Epizyme stock?
EPZM stock was acquired by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., JPMorgan Chase & Co., UBS Group AG, Redmile Group LLC, Sio Capital Management LLC, Opaleye Management Inc., Thrivent Financial for Lutherans and Eversept Partners LLC. View Insider Buying and Selling for Epizyme.
How do I buy shares of Epizyme?
Shares of EPZM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Epizyme's stock price today?
One share of EPZM stock can currently be purchased for approximately $17.00.
How big of a company is Epizyme?
Epizyme has a market capitalization of $1.18 billion and generates $10 million in revenue each year. The biopharmaceutical company earns $-134,300,000.00 in net income (profit) each year or ($2.18) on an earnings per share basis. Epizyme employs 131 workers across the globe.
How can I contact Epizyme?
Epizyme's mailing address is 400 TECHNOLOGY SQUARE, CAMBRIDGE MA, 02139. The biopharmaceutical company can be reached via phone at 617-229-5872 or via email at [email protected]
MarketBeat Community Rating for Epizyme (EPZM)
MarketBeat's community ratings are surveys of what our community members think about Epizyme and other stocks. Vote "Outperform" if you believe EPZM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EPZM will underperform the S&P 500 over the long term. You may vote once every thirty days.
Epizyme (NASDAQ:EPZM) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
12 Wall Street analysts have issued ratings and price targets for Epizyme in the last 12 months. Their average twelve-month price target is $23.00, suggesting that the stock has a possible upside of 35.29%. The high price target for EPZM is $26.00 and the low price target for EPZM is $16.00. There are currently 2 hold ratings and 10 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.83 | 2.92 | 2.92 | 2.90 |
| Ratings Breakdown: | 0 Sell Rating(s)
2 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $23.00 | $23.6364 | $23.00 | $23.00 |
| Price Target Upside: | 35.29% upside | 24.08% upside | 41.98% upside | 37.72% upside |
Epizyme (NASDAQ:EPZM) Consensus Price Target History
Epizyme (NASDAQ:EPZM) Analyst Ratings History
Show:
(Data available from 5/20/2016 forward)
Epizyme (NASDAQ:EPZM) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Epizyme (NASDAQ EPZM) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 21.50%
Institutional Ownership Percentage: 86.34%
Epizyme (NASDAQ EPZM) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 2/5/2018 | Matthew Ros | COO | Sell | 72,264 | $16.63 | $1,201,750.32 | 74,867 |  |
| 10/24/2017 | Peter Tai-Ching Ho | Insider | Sell | 15,000 | $16.44 | $246,600.00 | 23,123 | |
| 9/25/2017 | Peter Tai-Ching Ho | Insider | Sell | 15,000 | $16.81 | $252,150.00 | 23,123 | |
| 9/18/2017 | David M Mott | Director | Buy | 200,000 | $15.25 | $3,050,000.00 | 6,000 | |
| 8/24/2017 | Peter Tai-Ching Ho | Insider | Sell | 15,000 | $15.68 | $235,200.00 | 22,228 | |
| 7/24/2017 | Peter Tai-Ching Ho | Insider | Sell | 15,000 | $13.44 | $201,600.00 | 22,228 | |
| 6/30/2017 | Andrew E Singer | CFO | Sell | 3,024 | $15.50 | $46,872.00 | 40,529 | |
| 6/26/2017 | Peter Tai-Ching Ho | Insider | Sell | 15,000 | $14.87 | $223,050.00 | 22,228 | |
| 6/6/2017 | Robert A Copeland | Insider | Sell | 2,500 | $13.45 | $33,625.00 | 34,038 | |
| 5/25/2017 | Peter Tai-Ching Ho | Insider | Sell | 15,000 | $16.11 | $241,650.00 | 22,228 | |
| 5/2/2017 | Robert A Copeland | Insider | Sell | 5,000 | $17.44 | $87,200.00 | 36,538 | |
| 4/4/2017 | Robert A Copeland | Insider | Sell | 5,000 | $16.36 | $81,800.00 | 33,538 | |
| 3/31/2017 | Andrew E Singer | CFO | Sell | 2,013 | $17.09 | $34,402.17 | 36,175 | |
| 1/9/2017 | Andrew E Singer | CFO | Sell | 1,013 | $12.04 | $12,196.52 | 33,506 | |
| 12/9/2016 | Andrew E Singer | CFO | Sell | 1,013 | $11.03 | $11,173.39 | 32,060 | |
| 11/9/2016 | Andrew E Singer | CFO | Sell | 1,013 | $10.40 | $10,535.20 | 30,613 | |
| 10/10/2016 | Andrew E Singer | CFO | Sell | 1,013 | $9.72 | $9,846.36 | 29,167 | |
| 9/9/2016 | Andrew E Singer | CFO | Sell | 1,013 | $7.55 | $7,648.15 | 27,721 | |
| 8/9/2016 | Andrew E Singer | CFO | Sell | 1,013 | $9.05 | $9,167.65 | 26,274 | |
| 8/1/2016 | Robert A Copeland | Insider | Sell | 4,000 | $10.37 | $41,480.00 | 35,538 | |
| 7/11/2016 | Andrew E Singer | CFO | Sell | 1,013 | $10.36 | $10,494.68 | 24,828 | |
| 7/5/2016 | Robert A Copeland | Insider | Sell | 4,000 | $10.03 | $40,120.00 | 4,000 | |
| 6/9/2016 | Andrew E Singer | CFO | Sell | 1,013 | $12.49 | $12,652.37 | 23,382 | |
| 4/12/2016 | Andrew E Singer | CFO | Sell | 1,013 | $12.42 | $12,581.46 | 20,489 | |
| 3/9/2016 | Andrew E Singer | CFO | Sell | 1,006 | $9.33 | $9,385.98 | 19,036 | |
| 2/29/2016 | Peter Tai-Ching Ho | Insider | Buy | 636 | $7.47 | $4,750.92 | | |
| 2/10/2016 | Andrew E. Singer | CFO | Sell | 12,158 | $9.54 | $115,987.32 | 17,354 | |
| 1/12/2016 | Bay City Capital Fund V Co-Inv | Major Shareholder | Buy | 555,555 | $9.00 | $4,999,995.00 | | |
| 1/12/2016 | David M Mott | Director | Buy | 1,111,111 | $9.00 | $9,999,999.00 | | |
| 1/4/2016 | Robert A. Copeland | insider | Sell | 4,185 | $15.58 | $65,202.30 | | |
| 12/30/2015 | Robert J. Gould | Director | Sell | 32,108 | $18.01 | $578,265.08 | | |
| 12/9/2015 | Peter Tai-Ching Ho | Insider | Buy | 1,000 | $14.69 | $14,690.00 | | |
| 12/7/2015 | Robert A. Copeland | insider | Sell | 4,185 | $13.82 | $57,836.70 | | |
| 11/9/2015 | Robert A. Copeland | insider | Sell | 4,185 | $16.26 | $68,048.10 | | |
| 10/5/2015 | Robert A. Copeland | insider | Sell | 4,185 | $14.43 | $60,389.55 | | |
| 9/8/2015 | Robert A. Copeland | insider | Sell | 4,185 | $19.58 | $81,942.30 | | |
| 9/8/2015 | Robert J. Gould | CEO | Sell | 60,000 | $19.86 | $1,191,600.00 | | |
| 7/6/2015 | Robert A Copeland | Insider | Sell | 8,371 | $22.86 | $191,361.06 | | |
| 7/6/2015 | Robert J Gould | CEO | Sell | 60,000 | $23.22 | $1,393,200.00 | | |
| 5/5/2015 | Peter Tai-Ching Ho | Insider | Buy | 800 | $16.36 | $13,088.00 | | |
| 12/2/2014 | Peter Tai-Ching Ho | Insider | Buy | 1,000 | $21.17 | $21,170.00 | | |
| 11/17/2014 | Robert A Copeland | EVP | Sell | 20,000 | $22.68 | $453,600.00 | | |
| 11/3/2014 | Robert A Copeland | EVP | Sell | 20,000 | $25.47 | $509,400.00 | | |
| 11/3/2014 | Robert J Gould | CEO | Sell | 30,000 | $24.95 | $748,500.00 | | |
| 10/7/2014 | Robert A Copeland | EVP | Sell | 20,000 | $26.90 | $538,000.00 | | |
| 10/1/2014 | Robert J Gould | CEO | Sell | 30,000 | $26.28 | $788,400.00 | | |
| 10/1/2014 | Stephen Garbacz | Insider | Sell | 868 | $27.06 | $23,488.08 | | |
| 9/22/2014 | Robert A Copeland | EVP | Sell | 20,000 | $25.55 | $511,000.00 | | |
| 9/15/2014 | Eric Hedrick | Insider | Sell | 2,000 | $28.67 | $57,340.00 | | |
| 9/4/2014 | Carl Goldfischer | Director | Sell | 4,000 | $35.14 | $140,560.00 | | |
| 8/26/2014 | Bay City Capital Llc | Major Shareholder | Sell | 200,000 | $35.14 | $7,028,000.00 | | |
| 8/25/2014 | Bay City Capital Llc | Major Shareholder | Sell | 366,666 | $33.98 | $12,459,310.68 | | |
| 8/18/2014 | Robert A Copeland | EVP | Sell | 10,830 | $36.07 | $390,638.10 | | |
| 8/15/2014 | Ryan D Drant | Major Shareholder | Sell | 4,061 | $36.54 | $148,388.94 | | |
| 8/4/2014 | Jason P Rhodes | CFO | Sell | 30,000 | $29.74 | $892,200.00 | | |
| 8/4/2014 | Robert A Copeland | EVP | Sell | 20,000 | $29.42 | $588,400.00 | | |
| 7/15/2014 | Eric Hedrick | Insider | Sell | 2,000 | $31.35 | $62,700.00 | | |
| 7/7/2014 | Jason P Rhodes | CFO | Sell | 30,000 | $32.74 | $982,200.00 | | |
| 7/1/2014 | Robert J Gould | CEO | Sell | 30,000 | $31.53 | $945,900.00 | | |
| 6/23/2014 | Robert A Copeland | EVP | Sell | 20,000 | $28.42 | $568,400.00 | | |
| 6/16/2014 | Eric Hedrick | Insider | Sell | 2,000 | $26.42 | $52,840.00 | | |
| 6/16/2014 | Robert A Copeland | EVP | Sell | 25,012 | $26.38 | $659,816.56 | | |
| 6/2/2014 | Robert J Gould | CEO | Sell | 30,000 | $22.20 | $666,000.00 | | |
| 5/19/2014 | Robert Copeland | EVP | Sell | 5,000 | $22.28 | $111,400.00 | 17,561 | |
| 5/5/2014 | Jason Rhodes | CFO | Sell | 30,000 | $21.53 | $645,900.00 | 46,000 | |
| 5/5/2014 | Robert Copeland | EVP | Sell | 10,000 | $21.29 | $212,900.00 | 20,011 | |
| 5/1/2014 | Robert Gould | CEO | Sell | 30,000 | $21.91 | $657,300.00 | | |
| 4/28/2014 | Robert Copeland | EVP | Sell | 13,800 | $20.73 | $286,074.00 | 24,911 | |
| 4/7/2014 | Jason Rhodes | CFO | Sell | 25,000 | $20.05 | $501,250.00 | 34,000 | |
| 4/7/2014 | Robert Gould | CEO | Sell | 30,000 | $20.22 | $606,600.00 | | |
| 2/10/2014 | Celgene European Investment Co | major shareholder | Buy | 340,000 | $29.25 | $9,945,000.00 | | |
| 1/6/2014 | Jason Rhodes | CFO | Sell | 10,000 | $20.19 | $201,900.00 | 4,000 | |
| 12/16/2013 | Robert Copeland | EVP | Sell | 4,600 | $21.21 | $97,566.00 | 53,544 | |
| 12/2/2013 | Robert Copeland | EVP | Sell | 5,000 | $20.70 | $103,500.00 | 53,544 | |
| 11/15/2013 | M James Barrett | major shareholder | Buy | 406,500 | $19.68 | $7,999,920.00 | | |
| 6/5/2013 | David M Mott | Director | Buy | 400,000 | $15.00 | $6,000,000.00 | | |
| 6/5/2013 | Venture Fund I L.P. Astellas | Major Shareholder | Buy | 15,333 | $15.00 | $229,995.00 | | |
(Data available from 1/1/2013 forward)
Epizyme (NASDAQ EPZM) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Epizyme (EPZM) Price Target Raised to $25.00 at Wedbush
www.americanbankingnews.com - May 18 at 5:13 PM |
 | Epizyme (EPZM) to Present New Tazemetostat Data at ASCO and EHA
www.streetinsider.com - May 17 at 5:36 PM |
 | Epizyme to Present New Tazemetostat Data at the American Society of Clinical Oncology (ASCO) Annual Meeting and ...
globenewswire.com - May 17 at 5:36 PM |
 | Epizyme to Present New Tazemetostat Data at the American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association (EHA) Congress
finance.yahoo.com - May 17 at 5:36 PM |
| Epizyme Expected to Post Q2 2018 Earnings of ($0.47) Per Share (EPZM)
www.americanbankingnews.com - May 11 at 8:54 AM |
| SunTrust Banks Comments on Epizyme's Q2 2018 Earnings (EPZM)
www.americanbankingnews.com - May 11 at 8:54 AM |
| Oppenheimer Comments on Epizyme's Q2 2018 Earnings (EPZM)
www.americanbankingnews.com - May 11 at 8:54 AM |
| Epizyme (EPZM) to Post Q2 2018 Earnings of ($0.52) Per Share, Jefferies Group Forecasts
www.americanbankingnews.com - May 11 at 8:54 AM |
| Epizyme (EPZM) Expected to Announce Quarterly Sales of $2.17 Million
www.americanbankingnews.com - May 11 at 2:56 AM |
| Epizyme (EPZM) Upgraded by ValuEngine to Sell
www.americanbankingnews.com - May 10 at 12:47 PM |
| Epizyme Expected to Post Q1 2019 Earnings of ($0.39) Per Share (EPZM)
www.americanbankingnews.com - May 10 at 8:52 AM |
| Epizyme to Post Q2 2018 Earnings of ($0.55) Per Share, Leerink Swann Forecasts (EPZM)
www.americanbankingnews.com - May 10 at 6:54 AM |
| Epizyme (EPZM) Reports Narrower-Than-Expected Loss in Q1
finance.yahoo.com - May 9 at 5:06 PM |
| Zacks: Analysts Expect Epizyme (EPZM) Will Announce Earnings of -$0.57 Per Share
www.americanbankingnews.com - May 9 at 11:26 AM |
| Epizyme (EPZM) Posts Quarterly Earnings Results, Beats Estimates By $0.05 EPS
www.americanbankingnews.com - May 8 at 12:13 PM |
| EPIZYME, INC.
www.streetinsider.com - May 8 at 8:47 AM |
 | BRIEF-Epizyme Reports Q1 Loss Per Share Of $0.49
www.reuters.com - May 8 at 8:47 AM |
| Epizyme Reports First Quarter 2018 Financial Results and Provides Business Updates
finance.yahoo.com - May 8 at 8:47 AM |
| Epizyme Inc (NASDAQ:EPZM): Does The -21.86% Earnings Drop Reflect A Longer Term Trend?
finance.yahoo.com - May 8 at 8:47 AM |
| Epizyme: 1Q Earnings Snapshot
finance.yahoo.com - May 8 at 8:47 AM |
| Epizyme (EPZM) Reports Narrower-than-Expected Q1 Loss
finance.yahoo.com - May 8 at 8:47 AM |
 | Is a Beat in Store for Epizyme (EPZM) This Earnings Season?
www.zacks.com - May 7 at 5:12 PM |
| Epizyme Announces First Quarter 2018 Financial Reporting Date and Upcoming Conference Call
globenewswire.com - May 1 at 8:53 AM |
| Epizyme (EPZM) Scheduled to Post Earnings on Monday
www.americanbankingnews.com - April 30 at 9:41 AM |
| Epizyme (EPZM) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - April 30 at 3:48 AM |
| FY2019 Earnings Estimate for Epizyme (EPZM) Issued By SunTrust Banks
www.americanbankingnews.com - April 26 at 11:05 AM |
| FY2018 Earnings Forecast for Epizyme (EPZM) Issued By Wedbush
www.americanbankingnews.com - April 26 at 10:24 AM |
| Epizyme (EPZM) PT Set at $24.00 by Roth Capital
www.americanbankingnews.com - April 25 at 10:30 AM |
| Epizyme (EPZM) Rating Lowered to Strong Sell at ValuEngine
www.americanbankingnews.com - April 25 at 12:58 AM |
| BidaskClub Lowers Epizyme (EPZM) to Hold
www.americanbankingnews.com - April 25 at 12:26 AM |
| 'We Expect A Quick Resolution': Despite Partial Clinical Hold On Epizyme's Drug Candidate, Wedbush Stays Bullish
finance.yahoo.com - April 24 at 5:13 PM |
 | Epizyme Shares Drop After Partial Clinical Hold Placed On Lead Cancer Drug
feeds.benzinga.com - April 24 at 10:49 AM |
| Leerink Swann Analysts Give Epizyme (EPZM) a $24.00 Price Target
www.americanbankingnews.com - April 24 at 9:30 AM |
| Wedbush Lowers Epizyme (EPZM) Price Target to $20.00
www.americanbankingnews.com - April 24 at 9:12 AM |
| SunTrust Banks Reiterates Buy Rating for Epizyme (EPZM)
www.americanbankingnews.com - April 24 at 8:54 AM |
 | PRTA Jolted, FDA Strikes Down PFE's Herceptin Biosimilar, No Relief Yet For KMDA
www.nasdaq.com - April 24 at 8:45 AM |
| US STOCKS ON THE MOVE-Incyte, Epizyme, Shire, Valeritas
www.nasdaq.com - April 24 at 8:45 AM |
 | Biotech Analysis Central Pharma News: Orexigen's Last Resort, Epizyme's Partial Clinical Hold, Eli Lilly And Incyte's ...
seekingalpha.com - April 24 at 8:45 AM |
| $750,000.00 in Sales Expected for Epizyme (EPZM) This Quarter
www.americanbankingnews.com - April 24 at 4:48 AM |
| Epizyme (EPZM) Says US-based Enrollment of New Patients into Tazemetostat Clinical Trials is Temporarily on Hold
www.streetinsider.com - April 23 at 4:54 PM |
| Epizyme Provides Update Regarding Tazemetostat Clinical Program
finance.yahoo.com - April 23 at 4:54 PM |
| -$0.54 Earnings Per Share Expected for Epizyme (EPZM) This Quarter
www.americanbankingnews.com - April 22 at 3:08 AM |
| Why Is Epizyme (EPZM) Down 18% Since Its Last Earnings Report?
www.zacks.com - April 12 at 9:26 AM |
| Epizyme's (EPZM) "Buy" Rating Reiterated at HC Wainwright
www.americanbankingnews.com - April 12 at 12:29 AM |
| Epizyme (EPZM) Publishes Tazemetostat Phase I Data, Stock Up
finance.yahoo.com - April 11 at 5:03 PM |
| Epizyme (EPZM) Reports Publication of Tazemetostat Phase 1 Clinical Data in The Lancet Oncology
www.streetinsider.com - April 10 at 5:05 PM |
| Epizyme (EPZM) Downgraded to "Hold" at BidaskClub
www.americanbankingnews.com - April 10 at 10:25 AM |
| ValuEngine Downgrades Epizyme (EPZM) to Strong Sell
www.americanbankingnews.com - April 10 at 12:32 AM |
| Epizyme (EPZM) Upgraded by Zacks Investment Research to "Buy"
www.americanbankingnews.com - April 7 at 9:13 AM |
| Epizyme (EPZM) Expected to Announce Quarterly Sales of $750,000.00
www.americanbankingnews.com - April 7 at 4:43 AM |
Epizyme (NASDAQ:EPZM) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Epizyme (NASDAQ:EPZM) Income Statement, Balance Sheet and Cash Flow Statement
Epizyme (NASDAQ EPZM) Stock Chart for Sunday, May, 20, 2018
Loading chart…
